Page last updated: 2024-09-04

glucagon and empagliflozin

glucagon has been researched along with empagliflozin in 10 studies

Compound Research Comparison

Studies (glucagon)	Trials (glucagon)	Recent Studies (post-2010) (glucagon)	Studies (empagliflozin)	Trials (empagliflozin)	Recent Studies (post-2010) (empagliflozin)
26,039	1,498	3,054	1,429	313	1,395

Protein Interaction Comparison

Protein	Taxonomy	glucagon (IC50)	empagliflozin (IC50)
Sodium/glucose cotransporter 2	Homo sapiens (human)		0.0031

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (80.00)	24.3611
2020's	2 (20.00)	2.80

Authors

Authors	Studies
Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR	1
Ceriello, A; Genovese, S; Gronda, E; Mannucci, E	1
Andersen, G; Falk, A; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM	1
Abdul-Ghani, M; Adams, J; Al Jobori, H; Cersosimo, E; Daniele, G; DeFronzo, RA; Triplitt, C	1
Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D	1
Eckel, RH; Koh, KK; Lim, S	1
Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M	1
Abdel-Hamid, AAM; Firgany, AEL	1
Holst, JJ; Hædersdal, S; Knop, FK; Lund, A; Maagensen, H; Nielsen-Hannerup, E; van Hall, G; Vilsbøll, T	1
Abdelgani, S; Abdul-Ghani, M; Abu-Farha, M; Adams, J; Al-Mulla, F; Daniele, G; DeFronzo, RA; Del Prato, S; Khattab, A	1

Reviews

3 review(s) available for glucagon and empagliflozin

Article	Year
Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular diabetology, 2016, 08-27, Volume: 15, Issue:1 Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2016
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, Volume: 272 Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. International journal of clinical practice, 2018, Volume: 72, Issue:12 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide	2018

Trials

2 trial(s) available for glucagon and empagliflozin

Article	Year
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes, 2016, Volume: 65, Issue:5 Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors	2016
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:4 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period; Proinsulin; Treatment Outcome	2017

Article

Year

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

Diabetes, 2016, Volume: 65, Issue:5

Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors

2016

Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.

Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:4

Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period; Proinsulin; Treatment Outcome

2017

Other Studies

5 other study(ies) available for glucagon and empagliflozin

Article	Year
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Ketones; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2017
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5 Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors	2017
Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft, 2019, Volume: 224 Topics: Animals; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Caspase 3; Cell Proliferation; Cytokines; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Secreting Cells; Glucose Tolerance Test; Glucosides; Homeostasis; Immunohistochemistry; Insulin-Secreting Cells; Islets of Langerhans; Male; Prediabetic State; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors	2019
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. Diabetes, 2020, Volume: 69, Issue:12 Topics: Benzhydryl Compounds; Biphenyl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Metabolism; Gastric Emptying; Glucagon; Glucosides; Glycerol; Half-Life; Humans; Sodium-Glucose Transporter 2 Inhibitors	2020
Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients. Diabetes care, 2023, 05-01, Volume: 46, Issue:5 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucagon; Glucose; Humans; Insulin; Ketones; Norepinephrine	2023